Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis

Vaccine

Volumn 27, Issue 7, 2009, Pages 995-1001

  Valdés, Iris ^a   Hermida, Lisset ^a   Martín, Jorge ^a   Menéndez, Tamara ^a   Gil, Lázaro ^a   Lazo, Laura ^a   Castro, Jorge ^a   Niebla, Olivia ^a   López, Carlos ^a   Bernardo, Lídice ^b   Sánchez, Jorge ^a   Romero, Yaremis ^a   Martínez, Rafael ^a   Guzmán, María G ^b   Guillén, Gerardo ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

Author keywords

Adjuvants; Dengue virus; Green monkeys; Recombinant protein; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; CHIMERIC PROTEIN; ENVELOPE PROTEIN; FREUND ADJUVANT; HYBRID PROTEIN; OUTER MEMBRANE VESICLE VACCINE; P64K PROTEIN; POLYSACCHARIDE; RECOMBINANT PROTEIN PD5; SEROGROUP A CAPSULAR POLYSACCHARIDE; UNCLASSIFIED DRUG; VACCINE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DRUG FORMULATION; IMMUNIZATION; MEMBRANE VESICLE; MONKEY; NEISSERIA MENINGITIDIS; NONHUMAN; PRIMATE; PRIORITY JOURNAL; PROTECTION; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; DENGUE; DENGUE VACCINES; DENGUE VIRUS; NEISSERIA MENINGITIDIS; POLYSACCHARIDES, BACTERIAL; RECOMBINANT FUSION PROTEINS; SECRETORY VESICLES; SURVIVAL ANALYSIS; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 58849098138     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.11.106     Document Type: Article

References (47)

1. Alison J.J., Martin D.A., Karabatsos N., and Roehrig J.T. Detection of anti-arboviral immunoglobulin G by using a monoclonal antibody based capture enzyme-linked immunosorbent assay. J Clin Microbiol 38 5 (2000) 1827-1831
2. Bennett BT, Abee CR, Henrickson R. Nonhuman primates in biomedical research: Diseases. American College of Laboratory Animal Medicine Series; 1998.
3. Bernardo L., Izquierdo A., Álvarez M., Rosario D., Prado I., López C., et al. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res 80 2 (2008) 194-199
4. Bjune G., Hoiby E.A., Gronnesby J.K., Arnesen O., Fredriksen J.H., Halstensen A., et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338 8775 (1991) 1093-1096
5. Bray M., Men R., and Lai C.J. Monkeys Immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge. J Virol 70 6 (1996) 4162-4166
6. Burgdorf S., Lukacs-Kornek V., and Kurts C. The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation. J Immunol 176 11 (2006) 6770-6776
7. Chambers T.J., Chang S., Galler R., and Rice C. Flavivirus genome organization, expression and replication. Annu Rev Microbiol 44 (1990) 649-688
8. Chippaux J.P., Garba A., Ethevenaux C., Campagne G., de Chabalier F., Djibo S., et al. Immunogenicity, safety, and memory of different schedules of Neisseria meningitidis A/C-diphtheria toxoid conjugate vaccine in infants in Niger. Vaccine 22 25-26 (2004) 3303-3311
9. Churdboonchart V., Bhamarapravati N., and Peampramprecha S. Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. Am J Trop Med Hyg 44 5 (1991) 481-493
10. Fusco P.C., Michon F., Laude-Sharp M., Minetti C.A., Huang C.H., Heron I., et al. Preclinical studies on a recombinant group B meningococcal porin as a carrier for a novel Haemophilus influenzae type b conjugate vaccine. Vaccine 16 19 (1998) 1842-1849
11. Gubler D.J. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 10 2 (2002) 100-103
12. Guirakhoo F.R., Weltzin T.J., Chambers Z.X., Zhang K., Soike M., Ratterree J., et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 74 12 (2000) 5477-5485
13. Guirakhoo F., Arroyo J., Pugachev K.V., Miller C., Zhang Z.X., Weltzin R., et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 75 16 (2001) 7290-7304
14. Guzmán M.G., Rodríguez R., Rodríguez R., Hermida H., Álvarez M., Lazo L., et al. Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. Am J Trop Med Hyg 69 2 (2003) 129-134
15. Halstead S.B. Pathogenesis of dengue: challenge to molecular biology. Science 239 4839 (1988) 476-481
16. Hermida L., Bernardo L., Martín J., Álvarez M., Prado I., López C., et al. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24 16 (2006) 3165-3171
17. Izquierdo A., Bernardo L., Martín J., Santana E., Hermida L., Guillén G., et al. Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus. Virus Res 138 1-2 (2008) 135-138
18. Jennings H.J., Bhattacharjee A.K., Bundle D.R., Kenny C.P., Martin A., and Smith I.C. Structures of the capsular polysaccharides of Neisseria meningitidis as determined by 13C-nuclear magnetic resonance spectroscopy. J Infect Dis 136 Suppl. (1977) S78-S83
19. Joseph H., Ryall R., Bybel M., Papa T., MacLennan J., Buttery J., et al. Immunogenicity and immunological priming of the serogroup a portion of a bivalent meningococcal A/C conjugate vaccine in 2-year-old children. J Infect Dis 187 7 (2003) 1142-1146
20. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 5259 (1970) 680-685
21. Lee S.J., Evers S., Roeder D., Parlow A.F., Risteli J., Risteli L., et al. Mannose receptor-mediated regulation of serum glycoprotein homeostasis. Science 295 5561 (2002) 1898-1901
22. López C., Sánchez J., Hermida L., Zulueta A., and Marquez G. Cysteine mediated multimerization of a recombinant dengue E fragment fused to the P64k protein by immobilized metal ion affinity chromatography. Protein Expr Purif 34 2 (2004) 176-182
23. Lowell G.H., Ballou W.R., Smith L.F., Wirtz R.A., Zollinger W.D., and Hockmeyer W.T. Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides. Science 240 4853 (1988) 800-802
24. Markoff L., Pang X., Houng H., Falgout B., Olsen R., Jones E., et al. Derivation and characterization of a dengue type 1 host range-restricted mutant that is attenuated and highly immunogenic in monkeys. J Virol 76 7 (2002) 3318-3328
25. McGreal E.P., Miller J.L., and Gordon S. Ligand recognition by antigen-presenting cell C-type lectin receptors. Curr Opin Immunol 17 1 (2005) 18-24
26. Men R., Wyatt L., Tokimatsu I., Arakaki S., Shameen G., Elkins R., et al. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. Vaccine 18 27 (2000) 3113-3122
27. Morens D.M., Halstead S.B., and Repik P.M. Simplified plaque reduction assay for dengue viruses by semimicro methods in BHK 21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol 22 2 (1985) 250-254
28. Nøkleby H., Aavitsland P., O'Hallahan J., Feiring B., Tilman S., and Oster P. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine 25 16 (2007) 3080-3084
29. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., and Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23 17-18 (2005) 2191-2196
30. Pace D., and Pollard AJ. Meningococcal A, C Y and W-135 polysaccharide-protein conjugate vaccines. . Arch Dis Child 92 10 (2007) 909-915
31. Peeters C.C., Rumke H.C., Sundermann L.C., Rouppe van der Voort E.M., Meulenbelt J., Schuller M., et al. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 14 10 (1996) 1009-1015
32. Peppler M.S., and Frasch C.E. Protection against group B Neisseria meningitidis disease: effect of serogroup B polysaccharide and polymyxin B on immunogenicity of serotype protein preparations. Infect Immun 37 1 (1982) 264-270
33. Pérez A., Dickinson F., Cinza Z., Ruiz A., Serrano T., Sosa J., et al. Safety and preliminary immunogenicity of the recombinant outer membrane protein P64k of Neisseria meningitidis in human volunteers. Biotechnol Appl Biochem 34 Pt 2 (2001) 121-125
34. Putnak R.J., Coller B.A., Voss G., Vaughn D.W., Clements D., Peters I., et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 23 35 (2005) 4442-4452
35. Raviprakash K., Porter K.R., Kochel T.J., Ewing D., Simons M., Philllis I., et al. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J Gen Virol 81 Pt 7 (2000) 1659-1667
36. Rosenqvist E., Hoiby E.A., Bjune G., Aase A., Halstensen A., Lehmann A.K., et al. Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine. Dev Biol Stand 92 (1998) 323-333
37. Sierra G.V., Campa H.C., Varcacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F., et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 14 2 (1991) 195-210
38. Simmons M., Nelson W.M., Wu S.J., and Hayes C.G. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am J Trop Med Hyg 58 5 (1998) 655-662
39. Simmons M., Murphy G.S., and Hayes C.G. Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med Hyg 65 2 (2001) 159-161
40. Simmons M., Porter K.R., Hayes C.G., Vaughn D.W., and Putnak R. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J Virol 80 19 (2006) 9577-9585
41. Sotolongo F., Campa C., Casanueva V., Fajardo E.M., Cuevas I.E., and González N. Cuban meningococcal BC vaccine: experiences and contributions from 20 Years of application. MEDICC Rev. 9 1 (2007) 16-22 [http://www.medicc.org/mediccreview/]
42. Srivastava A., Putnak J.R., Warren R.L., and Hoke Jr. C.H. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine 13 13 (1995) 1251-1258
43. Velzing J., Groen J., Drouet M.T., van Amerongen G., Copra C., Osterhaus A.D.M.E., et al. Induction of protective immunity against Dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines. Vaccine 17 11-12 (1999) 1312-1320
44. Wetzler L.M. Immunopotentiating ability of neisserial major outer membrane proteins. Use as an adjuvant for poorly immunogenic substances and potential use in vaccines. Ann N Y Acad Sci 730 (1994) 367-370
45. Zhang Q., Lakshman R., Burkinshaw R., Choo S., Everard J., Akhtar S., et al. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom. Infect Immun 69 7 (2001) 4337-4341
46. Zollinger W.D., Mandrell R.E., Griffiss J.M., Altieri P., and Berman S. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J Clin Invest 63 5 (1979) 836-848
47. Zulueta A., Hermida L., Lazo L., Valdés I., Rodríguez R., López C., et al. The fusion site of envelope fragments from each serotype of dengue virus in the P64k protein, influence some parameters of the resulting chimeric construct. Biochem Biophys Res Commun 308 3 (2003) 619-626